Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05624450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Study acronym: TILIA
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 1 entry Trial sites expanded: 468 → 471 locations · Eligibility criteria expanded, about 6 words · Secondary endpoints: details revised at 4 of 18 entries Show 3 more changesShow less
    • Trial sites expanded: 468 → 471 locations
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 4 of 18 entries
  2. Trial sites expanded: 464 → 468 locationsv35
  3. Primary and study completion dates: Jun 19, 2026 to Nov 4, 2027 Enrollment target: 2870 to 3527 · Study sites: 451 to 464v34 Show 2 more changesShow less
    • Enrollment target: 2870 to 3527
    • Study sites: 451 to 464
  4. Site details revised at 7 of 451 sitesv33
  5. Site details revised at 7 of 451 sitesv32
Show 30 earlier versionsHide 30 earlier versions
  1. Site details revised at 341 of 451 sitesv31
  2. Study sites: 446 to 451v30
  3. Study sites: 447 to 446v29
  4. Study sites: 446 to 447v28
  5. Site details revised at 19 of 446 sitesv27
  6. Study sites: 443 to 446v26
  7. Study sites: 441 to 443v25
  8. Primary and study completion dates: Mar 17, 2025 to Jun 19, 2026 Study sites: 437 to 441v24 Show 1 more changeShow less
    • Study sites: 437 to 441
  9. Study sites: 430 to 437v23
  10. Enrollment target: 2902 to 2870 Study sites: 408 to 430 · Eligibility criteria expanded, about 13 words · Secondary endpoints revised (18)v22 Show 3 more changesShow less
    • Study sites: 408 to 430
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (18)

    See this version in full on ClinicalTrials.gov ↗

  11. Re-verified, no change to tracked fieldsv21
  12. Study sites: 384 to 408v20
  13. Study sites: 383 to 384v19
  14. Study sites: 381 to 383v18
  15. Site details revised at 9 of 381 sitesv17
  16. Study sites: 382 to 381v16
  17. Study sites: 379 to 382v15
  18. Study sites: 375 to 379v14
  19. Study sites: 368 to 375v13
  20. Study sites: 354 to 368v12
  21. Study sites: 341 to 354v11
  22. Study sites: 336 to 341v10
  23. Study sites: 317 to 336v9
  24. Enrollment target: 2984 to 2902 Secondary endpoints revised (18) · Site details revised at 4 of 317 sites · Eligibility criteria expanded, about 2 wordsv8 Show 3 more changesShow less
    • Secondary endpoints revised (18)
    • Site details revised at 4 of 317 sites
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  25. Primary and study completion dates: May 9, 2024 to Mar 17, 2025 Enrollment target: 2352 to 2984 · Study sites: 236 to 317 · Eligibility criteria expanded, about 38 words · 1 morev7 Show 4 more changesShow less
    • Enrollment target: 2352 to 2984
    • Study sites: 236 to 317
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: details revised at 9 of 18 entries

    See this version in full on ClinicalTrials.gov ↗

  26. Primary and study completion dates: Dec 12, 2024 to May 9, 2024v6
  27. Primary and study completion dates: May 9, 2024 to Dec 12, 2024 Study sites: 221 to 236v5 Show 1 more changeShow less
    • Study sites: 221 to 236
  28. Study sites: 180 to 221v4
  29. Study sites: 125 to 180 Secondary endpoints: details revised at 1 of 18 entriesv3 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 18 entries
  30. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 125 · Start date changed from estimate of Dec 1, 2022 to Dec 13, 2022v2 Show 2 more changesShow less
    • Study sites: 0 to 125
    • Start date changed from estimate of Dec 1, 2022 to Dec 13, 2022
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Trial Details
NCT Number NCT05624450
Lead Sponsor AstraZeneca
Conditions Viral Lung Infection and Acute Respiratory Failure
Enrollment 3,527 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov